Published • loading... • Updated
This Phase 2 ASX Biotech Has a Drug That Is One of Its Kind and Has Been Progressing Nicely!
Summary by Stocks Down Under
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
This Phase 2 ASX Biotech Has a Drug That Is One of Its Kind and Has Been Progressing Nicely!
Phase 2 ASX Biotech Prescient Therapeutics (ASX:PTX) has spent the better part of a decade building up to the point it is at now. 2026 has become the year in which the investment case is finally coming into focus. PTX‑100 is the world’s first GGTase‑1 inhibitor to enter human trials, and it remains the only drug of its class being evaluated in relapsed and refractory cutaneous T‑cell lymphoma (r/r CTCL). It is in a Phase 2 programme and it the t…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
